Factor XIIa is a kinetically favorable plasminogen activator

Thrombosis and Haemostasis

Volumn 82, Issue 3, 1999, Pages 1041-1046

  Schousboe, Inger ^a   Feddersen, Karina ^a   Roøjkjær, Rasmus ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 12A; PLASMINOGEN; PLASMINOGEN ACTIVATOR; POLYCLONAL ANTIBODY; UROKINASE;

ARTICLE; BLOOD CLOT LYSIS; COMPETITIVE INHIBITION; ENZYME ACTIVATION; FIBRINOLYSIS; HUMAN; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL;

EID: 0032872791     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614326     Document Type: Article

References (29)

1. Bernardo MM, Day DE, Halvorson HR, Olson ST, Shore JD. Surface-independent acceleration of factor XII activation by zinc ions. II: Direct binding and fluorescence studies. J Biol Chem 1993; 268: 12477-83.
2. Røjkjær R, Schousboe I. The surface-dependent autoactivation mechanism of factor XII. Eur J Biochem 1997; 243: 160-6.
3. Ichinose A, Fujikawa K, Suyama T. The activation of pro-urokinase by plasma kallikrein and its activation by thrombin. J Biol Chem 1986; 261: 3486-9.
4. Lenich C, Pannell R, Gurewich V. Assembly and activation of the intrinsic fibrinolytic pathway on the surface of human endothelial cells in culture. Thromb Haemost 1995; 74: 698-703.
5. Loza JP, Gurewich V, Johnstone M, Pannell R. Platelet-bound prekallikrein promotes pro-urokinase-induced clot lysis: a mechanism for targeting the factor XII dependent intrinsic pathway of fibrinolysis. Thromb Haemost 1994; 71: 347-52.
6. Glueck HI, Roehill W. Myocardial infarction in a patient with Hageman (factor XII) defect. Ann Intern Med 1966; 64: 390-6.
7. Hedner U, Nilsson IM. Acquired anticoagulants against factor XI and XII in patients with severe thrombotic disease. 16th Internat Congr Hematology, Kyoto, Japan, 1976; (abstract no 8/88): 341.
8. Lämmle B, Wuillemin WA, Huber I, Krauskopf M, Zürcher C, Pflugshaupt R, Furlan M. Thromboembolism and bleeding tendency in congenital factor XII deficiency - A study on 74 subjects from 14 Swiss families. Thromb Haemost 1991; 65: 117-21.
9. Motta G, Røjkjær R, Hasan AAK, Cines DB, Achmaier AH. High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: a novel mechanism for contact activation. Blood 1998; 91: 516-28.
10. Røjkjær R, Hasan AAK, Motta G, Schousboe I, Schmaier AH. Factor XII does not initiate prekallikrein activation on endothelial cells. Thromb Haemost 1998; 80: 74-81.
11. Levi M, Hack E, DeBoer JP, Brandjes DPM, Büller HR, ten Cate JW. Reduction of the contact activation related fibrinolytic activity in factor XII deficient patients. J Clin Invest 1991; 88: 1155-60.
12. Miles LA, Greengard JS, Griffin JH. A comparison of the abilities of plasma kallikrein, β-factor XIIa, factor XIa and urokinase to activate plasminogen. Thromb Res 1983; 29: 407-17.
13. Goldsmith GH. Saito H, Ratnoff OD. The activation of plasminogen by Hageman factor (factor XII) and Hageman factor fragments. J Clin Invest 1978; 62: 54-60.
14. 2+. Blood Coag Fibrinol 1997; 8: 97-104.
15. Rånby M. Studies on the kinetics of plasminogen activation by tissue plasminogen activator. Biochim Biophys Acta 1982; 704: 461-9.
16. 2-terminal lysine plasminogen to plasmin. Biochim Biophys Acta 1977; 480: 275-81.
17. 2-terminal glutamic acid plasminogen to plasmin. Biochim Biophys Acta 1977; 481; 638-47.
18. Ellis V, Scully MF, Kakkar VV. Plasminogen activation by single-chain urokinase in functional isolation. A. Kinetic study. J Biol Chem 1987; 262: 14998-15003.
19. Ellis V. Behrendt N, Danø K. Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem 1991; 266: 12752-8.
20. Lewis ML, Nachtwey DS, Damron KL. A miniaturized fibrinolytic assay for plasminogen activators. Thromb Res 1991; 64: 223-34.
21. Revak SD, Cochrane CG, Johnson AR, Hugli TE. Structural changes accompanying enzymic activation of human Hageman factor. J Clin Invest 1974; 54: 619-27.
22. Kaplan AP, Austen KF. A prealbumin activator of prekallikrein II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J Exp Med 1971; 133: 696-712.
23. Jespersen J, Gram J, Astrup T. The autodigestion of human plasmin follows a bimolecular mode of reaction subject to product inhibition. Thromb Res 1986; 37: 395-404.
24. Binnema DJ, Van Iersel JJL, Dooijewaard G. Quantitation of urokinase antigen in plasma and culture media by use of an ELISA. Thromb Res 1986; 43: 569-77.
25. Dooijewaard G, DeBoer A, Turion PN, Cohen AF, Breimer DD, Kluft C. Physical exercise induces enhancement of urokinase-type plasminogen activator (uPA) levels in plasma. Thromb Haemost 1992; 65: 42-86.
26. Grøndahl-Hansen J, Agerlin N, Munkholm-Larsen P, Bach F, Nielsen LS, Dombernowsky P, Danø K. Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer. J Lab Clin Med 1988; 111: 42-51.
27. Binnema DJ, Dooijewaard G, van Iersel JJ, Turion PN, Kluft C. The contact-system dependent plasminogen activator from human plasma: identification and characterization. Thromb Haemost 1990; 64: 390-7.
28. Reddigari SR, Shibayama Y, Brunnée T, Kaplan AP. Human Hageman factor (factor XII) and High Molecular Weight Kininogen compete for the same binding site on human umbilical vein endothelial cells. J Biol Chem 1993; 268: 11982-7.
29. Bugge TH, Flick MJ, Danton MJS, Daugherty CC, Rømer J, Danø K, Carmeliet P, Collen D, Degen JL. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci USA 1996; 93: 5899-04.